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Abstract
Pre-clinical data have shown that tissue 
level effects stemming from bisphosphonate-
induced suppression of bone remodeling 
can result in bone that is stronger yet more 
brittle. Raloxifene has been shown to reduce 
bone brittleness through non-cellular mecha-
nisms. The goal of this work was to test the 
hypothesis that raloxifene can reverse the 
bone brittleness resulting from bisphospho-
nate treatment. Dog and mouse bone from 
multiple bisphosphonate dosing experiments 
were soaked in raloxifene and then assessed 
for mechanical properties. Mice treated with 
zoledronate in vivo had lower post-yield me-
chanical properties compared to controls. 
Raloxifene soaking had significant positive 
effects on select mechanical properties of 
bones from both vehicle and zoledronate 
treated mice. Although the effects were 
blunted in zoledronate bones relative to ve-
hicle, the soaking was sufficient to normalize 
properties to control levels. Additional studies 
showed that raloxifene-soaked bones had a 
significant positive effect on cycles to failure 
(+114%) compared to control-soaked mouse 
bone. Finally, raloxifene soaking significantly 
improved select properties of ribs from dogs 
treated for 3 years with alendronate. These 
data show that ex vivo soaking in raloxifene 
can act through non-cellular mechanisms to 
enhance mechanical properties of bone pre-
viously treated with bisphosphonate. We also 
document that the positive effects of ralo-
xifene soaking extend to enhancing fatigue 
properties of bone.
Keywords: bisphosphonate, toughness, 
mechanical properties, zoledronate, alendro-
nate.
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Resumen
EL RALOXIFENO INVIERTE FRAGILIDAD 
ÓSEA INDUCIDA POR EL TRATAMIENTO 
ANTI-REMODELACIÓN Y AUMENTA LA RE-
SISTENCIA A LA FATIGA A TRAVÉS DE ME-
CANISMOS MEDIADOS NO CELULARES.
Los datos preclínicos han demostrado que 
los efectos a nivel de tejido que se derivan de 
la supresión del remodelado óseo inducida 
por bifosfonatos puede dar como resultado 
un hueso que es más fuerte pero más frágil. 
Está comprobado que el raloxifeno reduce la 
fragilidad ósea a través de mecanismos no ce-
lulares. El objetivo de este trabajo fue probar la 
hipótesis de que el raloxifeno puede revertir la 
fragilidad ósea resultante del tratamiento con 
bifosfonatos. Se emplearon huesos de perro 
y ratón de múltiples experimentos con dife-
rentes dosis de bifosfonatos los cuales fueron 
sumergidos en raloxifeno y luego se evaluaron 
sus propiedades mecánicas. Ratones tratados 
con zoledronato in vivo mostraron propieda-
des mecánicas post-rendimiento más bajas en 
comparación con los controles. Luego de su-
mergirlos en raloxifeno se observaron efectos 
positivos significativos en algunas propiedades 
biomecánicas tanto en los huesos de ratones 
tratados con vehículo como con zoledronato. 
Aunque los efectos se atenuaron en los hue-
sos tratados con zoledronato en relación con 
los tratados con vehículo, el raloxifeno fue su-
ficiente para normalizar las propiedades a ni-
veles basales. Estudios adicionales mostraron 
que los huesos sumergidos en raloxifeno tuvie-
ron un efecto positivo significativo en los ciclos 
de fractura (+ 114%) en comparación con los 
huesos de ratón sumergido en vehículo. Final-
mente, el raloxifeno mejoró significativamente 
las propiedades de costillas de perros tratados 
durante 3 años con alendronato. Estos datos 
muestran que la inclusión ex vivo en raloxifeno 
puede actuar a través de mecanismos no celu-
lares para mejorar las propiedades mecánicas 
de huesos previamente tratado con bifosfona-
tos. También documentamos que los efectos 
positivos del raloxifeno mejoran las propieda-
des de fatiga del hueso.
Palabras clave: bifosfonato, dureza, propieda-
des mecánicas, zoledronato, alendronato.
Introduction
A bone’s mechanical properties, specifi-
cally those related to displacement and en-
ergy absorption, can be described as being 
brittle or ductile.1-3 A ductile bone is able to 
undergo significant displacement and absorb 
significant energy following the manifestation 
of permanent damage. Conversely, a brittle 
bone fails soon after the initiation of permanent 
damage. Classic clinical examples of these ex-
tremes are developing bone and osteopetrotic 
bone, respectively.4 In the laboratory, decalci-
fication of a bone makes it extremely ductile,5 
while removal of the organic material (using 
heat) makes it extremely brittle.6 In general, in-
creasing the ductility of bone is advantageous 
for improving its resistance to fracture.1 
The goal of anti-osteoporotic interventions 
is to reduce fracture.7 Whether or not a bone 
fractures depends on several factors, includ-
ing bone mass, propensity to fall, and the me-
chanical properties of the bone tissue.1 Inter-
ventions such as bisphosphonates primarily 
reduce fracture risk by increasing bone mass 
which leads to improvements in whole bone 
mechanical properties.8 In many cases though, 
improving bone mass and bone strength 
comes at the expense of changes to the tissue 
which are not completely positive. Pre-clinical 
data in dogs9-14 and mice (C57BL/6),15 have 
shown that suppression of bone remodeling by 
bisphosphonate treatment can result in bone 
that has higher ultimate force yet lower tough-
ness. It has been hypothesized that this reduc-
tion in tissue toughness, brought about by del-
eterious changes to the tissue level properties 
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(altered mineral heterogeneity,16,17 properties 
of mineral crystals,16 collagen cross-linking,18,19 
microdamage),9,20 is linked to atypical femoral 
fractures.21,22 
Enhancing the ductility of bone at the tis-
sue level has been shown to occur with ana-
bolic treatment due to its remodeling away 
older tissue and replacing it with new matrix. 
Raloxifene (RAL), an FDA approved selective 
estrogen receptor modulator, also reduces 
brittleness of bone,23,24 but through an alterna-
tive mechanism involving non-cellular media-
ted modification of tissue hydration.25,26 The 
goal of this work was to test the hypothesis 
that in vitro exposure to raloxifene is sufficient 
to neutralize thebone brittleness that occurs 
following bisphosphonate treatment.
Methods
Animal experiments. The bones utilized in 
this report come from three different experi-
ments. All sample sizes can be found in the 
data tables and figures. In experiment one, 
designed to determine if zoledronate pro-
duced effects on mechanical properties, male 
C57BL/6 mice were treated saline or zoledro-
nate (ZOL) for 8 weeks, from 16 to 24 weeks 
of age.15 At 24 weeks of age, bilateral femora 
were removed, wrapped in saline-soaked 
gauze, and frozen at -20 ºC until analysis. 
Mechanical testing of the right femora was 
performed and these data have been previ-
ously reported.15 Left limbs, used in this cur-
rent work, were thawed, soaked in RAL for 7 
days and then subjected to mechanical test-
ing. These results were compared to those 
from the contralateral femora that was tested 
without soaking.
In experiment two, bilateral femora from 
untreated 16 week old male C57BL/6 mice 
were collected to study the fatigue properties 
of mouse bone. A subset of these bones were 
used in the current work.
In experiment three, skeletally mature fe-
male beagles were treated for three years with 
daily oral saline (10 ml) or alendronate (ALN, 
0.2 mg/kg/day in 10 ml).10 After three years of 
treatment, ribs were dissected free, wrapped 
in saline-soaked gauze, and frozen at -20 ºC 
until analysis. All animal experiments were 
approved by the Indiana University School of 
Medicine IACUC prior to the live animal ex-
periments.
Raloxifene soaking. RAL was purchased 
from Sigma and dissolved in DMSO following 
previously published protocols.25 Bones were 
soaked in 1% penicillin-streptomycin/phos-
phate buffered saline solution, with either 2 
µM DMSO or 2 µM RAL at 37 ºC for 14 (ex-
periment 3), 7 (experiments one) or 2 (experi-
ment two) days, changing the solution every 
2-3 days.
Peripheral quantitative and microcomputed 
tomography (pQCT, microCT). To normalize 
mechanical properties, one femur from each 
mouse in all experiments was scanned to 
determine cortical bone geometry at 50% of 
bone length. MicroCT scans were obtained 
using a Skyscan 1176 scanner at 9 micron 
resolution. Scan reconstruction and analysis 
at the mid-diaphysis were conducted using 
manufacturer software combined with a cus-
tom MATLAB program.27 All ribs from experi-
ment 3 were scanned using pQCT (Norland 
Stratec XCT Research SA+) at the spot of 
greatest curvature (approximately midrib).28 
A single slice was imaged at this spot using 
a scanning resolution of 0.07 x 0.07 x 0.50 
mm. Anterior–posterior diameter (APdia, mm) 
and cross-sectional moment of inertia (CSMI, 
mm4) were obtained using standard scanner 
software for estimation of material properties.
Mechanical testing. Bones from experi-
ment one were tested in four-point bending.27 
Bones were placed anterior surface down on 
a bottom support span of 9 mm; the upper 
support span was 3 mm wide centered at the 
mid-diaphysis. Testing occurred at a displace-
ment rate of 2 mm/min and load/displacement 
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data collected. Analysis of mechanical data 
test curves was done using a custom MAT-
LAB program that integrates the CT data with 
the load/displacement data to produce both 
structural (yield/ultimate load, stiffness, pre-
yield/post-yield/total displacement, pre-yield/
post-yield/total energy) and material (yield/
ultimate stress, modulus, strain, toughness) 
properties. The geometric properties used 
for normalization of both right and left bones 
was based on CT scanning of only one bone. 
Based on unpublished data from our labora-
tory, as well as published studies,29 there is 
minimal right/left difference in geometry within
an animal, thus supporting our use of CT data 
from one bone within an animal for normaliza-
tion ofthe contralateral bone.
Mouse femora in experiment two were 
subjected to fatigue loading in four-point 
bending. Ten paired femurs were soaked in 
either PBS (left) or RAL (right) and then tested 
in fatigue using a sinusoidal waveform (load-
ing between the force corresponding to 15% 
and 85% of the ultimate stress (determined 
from monotonic test on another set of bones) 
with a frequency of 0.5 Hz for the first ten 
preconditioning cycles and 4 Hz for the rest 
of the test. Femurs were hydrated through-
out the test with the use of a heated saline 
bath (37°C) that contained 2% Pen-Strep. Any 
tests that reached 300,000 were terminated 
without failure. 
Dog ribs were tested in three-point ben-
ding.28 After thawing to room temperature, 
specimens were placed on a three-point 
bending fixture (bottom support span = 25 
mm) with the convex surface of the rib fac-
ing up. The upper support contact point was 
at the midpoint of the specimen, matching 
the site of pQCT analyses. Specimens were 
loaded to failure at a displacement rate of 20 
mm/minute, and load vs. displacement data 
were collected. Structural mechanical prop-
erties were determined and material proper-
ty estimations were calculated as outlined 
above.
Statistics. All statistical tests were per-
formed using SAS software. Data from experi-
ments one and three were compared using 
two-way ANOVA with repeated measures (to 
account for right/left limbs). Statistically sig-
nificant effects of in vivo treatment, soaking, 
and interactions (followed by analysis of sim-
ple main effects) between those two variables 
were determined using a p<0.05. Data from 
experiment two were compared using paired 
t-tests. All data are presented as mean and 
standard deviations.
Results
Experiment 1. There was a significant 
main effect of in vivo ZOL treatment for pre-
yield (+27%), post-yield (-37%), and total dis-
placement (-27%) and all estimates of mate-
rial properties relative to animals treated with
vehicle (VEH) (Table 1, Figure 1). There was 
a significant main effect of RAL-soaking on 
post-yield displacement (+10%), total dis-
placement (+10%), and total strain (+26%) 
relative to the contralateral limbs that were 
not soaked. Significant interactions existed 
for ultimate load, post-yield energy and total 
energy where, in all three cases, the effect 
of RAL-soaking was significantly greater in 
bones from animals treated with VEH in vivo 
compared to those treated with ZOL. In sum-
mary, the effects of raloxifene soaking were 
less effective in ZOL-treated animals, yet suf-
ficient to return select mechanical properties 
to those of normal untreated animals.
Experiment 2. PBS-soaked control 
bones subjected to fatigue loading failed at 
116,005+90,767 cycles. RAL-soaked bones 
had 1.7-fold longer fatigue life (p=0.019), 
202,894+125,607 cycles (Figure 2A). One of 
ten PBS-soaked bones (10%) and five of ten 
RAL-soaked bones (50%) were stopped at 
300,000 cycles without failure. The majority 
of paired bones followed the trend of RAL be-
ing higher than PBS yet there were three sets 
that were either unchanged (both reached 
300,000 cycles) or showed modest reductions 
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Table 1. Mechanical properties of mouse femora in 4-point bending.
Vehicle-treatment Zoledronate-treatment In vivo 
treatment 
(VEH vs ZOL)
Soaking (None 
or RAL)
Interaction
Control (n=20)
RAL – soaking 
(n=20)
Control (n=17)
RAL – soaking 
(n=17)
Ultimate Load, N 21.3± 3.7 23.4±3.8 * 27.8±4.1 25.8±6.4 0.001 0.500 0.0001
Stiffness, N/mm 115±36 133±47 * 153±45 162±60 0.189 0.917 0.025
Yield energy, mJ 0.72±0.38 1.06±0.64 1.48±0.63 1.63±1.1 0.0004 0.170 0.622
Post-yield energy, mJ 9.57±3.5 13.2±4.5 * 8.3±3.6 9.4±3.9 0.021 0.0004 0.047
Energy to failure, mJ 10.3±3.4 14.2±4.5 * 9.8±3.3 11.0±3.6 0.073 0.0002 0.038
US, MPa 252±25 266±33 286±31 286±45 0.001 0.119 0.551
Strain to failure, µE 94,084±26,788 123,289±43,715 73,113±18,473 87,851±25,203 0.002 0.286 0.595
Modulus, MPa 9.07±1.6 9.67±2.5 9.22±1.9 9.23±1.8 0.0005 0.002 0.267
Toughness, , MJ/m3 17.2±5.2 22.9±6.3 14.9±5.3 17.7±5.3 0.001 0.159 0.880
* vs control within treatment in post-hoc test following significant interaction in two-way ANOVA. Data presented as 
mean and standard deviation. RAL – raloxifene; VEH – vehicle; ZOL – zoledronate. 
Figure 1. Ex vivo soaking in raloxifene significantly 
affects displacement properties of mouse bone 
previously vehicle (VEH) and zoledronate (ZOL). A. 
Total displacement during four-point bending was 
significantly affected by in vivo treatment with ZOL. 
Ex vivo soaking in raloxifene (RAL) significantly im-
proved displacement in both VEH and ZOL treated 
animals with no interaction between the two vari-
ables (p=0.379). B. There was a significant effect 
of in vivo ZOL treatment on pre-yield displacement 
(p=0.003) with no effect of RAL-soaking or an in-
teraction between variables (p=0.234 and 0.705, 
respectively). C. Post-yield displacement showed 
a similar pattern as total displacement.
1A 1B
1C
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with RAL (Figure 2B). The RAL-soaked bones 
had an ~114% average increase in cycles to 
failure versus their contralateral PBS-soaked 
control bone. 
Experiment 3. There were no significant 
main effects of alendronate treatment (Table 
2). There was a significant main effect of RAL 
soaking on energy to failure (+16%), post-yield 
energy (+21%), toughness (+38%) and post-
yield toughness (+43%) (Figure 3).
Discussion
A bone made of brittle material is at an 
increased risk of fracture even if bone mass 
is increased. There are several illustrative 
examples, such as the clinical condition of 
osteopetrosis, where bone mass is high 
yet fractures are quite prevalent,30 and pre-
clinical models of osteogenesis imperfecta 
when drugs that increase bone mass are 
insufficient to normalize mechanical proper-
ties.31,32 We and other have documented that 
bisphosphonates result in tissue brittleness, 
both in dogs and more recently in C57BL/6 
mice.13,15,28 Given that bisphosphonates have 
long-lasting effects even after treatment with-
drawal,33,34 finding active ways to neutralize/
reverse the brittleness brought on by remode-
ling suppression necessitate new approaches. 
In this proof-of-concept study, we show that 
raloxifene can overcome the tissue brittleness 
caused by bisphosphonates through non-
cellular mechanisms.
Raloxifene has a long history of having 
positive effects on bone.35 It is FDA approved 
for the treatment and prevention of fracture in 
post-menopausal women.36-38 Although the 
mechanism of action was originally thought to 
be related to suppressed osteoclast action, 
there remained a known disconnect between 
changes in bone mass and fracture risk re-
duction.39 Recently, our lab has documented 
a potential explanation for this disconnect 
by showing that raloxifene can act through 
non-cellular mechanisms to increase tissue 
hydration.25,26 This effect is associated with 
2A 2B
Figure 2. Ex vivo soaking in raloxifene (RAL) significantly improves fatigue properties of mouse bone. 
A. Cycles to failure were significantly higher in bones soaked in raloxifene compared to contralateral 
controls soaked in PBS. Data presented as mean and standard deviation. *p<0.05 in paired t-test versus 
PBS. B. Number of cycles to failure of individual sets of paired bones with each set representing the right 
and left bone of a given mouse. Note that bones not failing by 300,000 cycles were stopped.
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improvements in mechanical properties, spe-
cifically post-yield properties.25 Although the 
details regarding how raloxifene increases 
hydration remain to be clearly elucidated, the 
most recent findings point to binding of raloxi-
fene at the mineral/collagen interface.26
In the experiments described herein, raloxi-
fene soaking of the bones from animals treat-
ed with vehicle (thus normal animals) resulted 
in robust positive responses to properties that 
are influenced by post-yield behavior. This is 
consistent with previous work from both dog 
and human tissue soaked in raloxifene.25 Ral-
oxifene’s significant positive effect on post-
Vehicle-treatment Alendronate-treatment In vivo 
treatment 
(VEH vs 
ALN)
Soaking 
(PBS or 
RAL)
Interaction
PBS-soaking
(n=9)
RAL-soaking
(n=9)
PBS-soaking
(n=10)
RAL-soaking
(n=10)
Ultimate Load, N 88±25 100±21 90±22 89±16 0.617 0.285 0.184
Stiffness, N/mm 165±53 200±35 176±51 174.5±42 0.687 0.209 0.131
Post yield displacement, mm 4.26±1.46 4.74±0.66 3.85±1.39 4.23±1.77 0.363 0.119 0.865
Total displacement, mm 4.59±1.43 5.16±0.74 4.19±1.34 4.56±1.19 0.325 0.087 0.697
Post-yield energy, mJ 312±91 404 ±134 286±119 319±84 0.234 0.012 0.188
US, MPa 114±53 148±49 128±85 124±70 0.859 0.196 0.085
Modulus, MPa 6049±2526 7868±2067 * 7240±4023 6790±3120 0.966 0.239 0.041
Post-yield toughness, MJ/m3 13.6±4.4 22.6±10.8 12.3±7.6 14.7±8.1 0.175 0.006 0.073
Table 2. Mechanical properties of dog ribs in 3-point bending.
* vs control within treatment in post-hoc test following significant interaction in two-way ANOVA. Data presented as 
mean and standard deviation. PBS – phosphate buffered saline; RAL – raloxifene; VEH – vehicle; ALN – alendronate.
Figure 3. Ex vivo soaking in raloxifene restores displacement properties of ribs from vehicle (VEH) and 
alendronate (ALN)-treated dogs. Energy to failure (A) and toughness (B) were both was significantly 
higher in bones soaked in raloxifene (RAL) compared to those soaked in PBS.
3B3A
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yield and total displacement carried over to 
bones from animals treated with zoledronate 
in vivo. This effect resulted in RAL-soaked 
bones from zoledronate-treated animals hav-
ing similar post-yield and total displacement 
values as normal bones. Simply stated, RAL-
soaking normalized the mechanical pheno-
type of zoledronate bone.There were other 
mechanical properties where the positive ef-
fects of raloxifene soaking were significantly 
attenuated in bones from animals treated in 
vivo with zoledronate as evident by the sig-
nificant interaction in ultimate load, post-yield 
and total energy.
Contrary to previous work from these 
same animals,12,13,28 the mechanical tests of 
dog ribs did not reveal significant effects of in 
vivo alendronate treatment. Properties most 
often noted as being negatively affected by 
alendronate, such as toughness, were non-
significantly lower (-10%; p=0.15 main effect).
Of note is that sample sizes here were lower 
than in previous reports (n=12/group) because 
specimens from some animals were no longer 
available, thus reducing the power in the sta-
tistical tests. It is also possible that soaking 
itself affected the ability to see effects of ALN 
as several of the parameters from PBS-soaked 
bones were qualitatively different compared 
to previous work28 although it should be ac-
knowledged that these were different ribs and 
thus different properties might not be unex-
pected. Despite the lack of significant differ-
ences brought about by ALN, there remained 
significant main effects of raloxifene soaking 
on post-yield and total displacement and en-
ergy absorption. Consistent with the mouse 
bones in experiment 1, there was a suggestion 
of an interaction in the effect of RAL-soaking, 
being mainly driven by the response of bones 
from VEH-treated animals. One plausible 
explanation is that changes to mineral and 
collagen brought about by bisphosphonate-
treatment16,18,19 alter the ability for raloxifene to 
modify hydration and this is more evident in a 
species that undergo intracortical remodeling 
(and thus suppressed intracortical remodel-
ing). Alternatively, differences in bisphospho-
nate (alendronate vs zoledronate), duration of 
treatment (two months in mouse vs 3 years in 
dog), or bone (rib versus femur) could be the 
underlying reason for differences between the 
two experiments.
The precise mechanisms underlying tis-
sue-level brittleness with bisphosphonates 
remains unclear. Altered mineral heteroge-
neity,16,17 properties of mineral crystals,16 col-
lagen cross-linking,18,19 microdamage9,20 have 
all been documented in various model sys-
tems (including humans). Many of the chang-
es in cortical bone are associated with the 
change in intracortical remodeling, yet data 
exist showing lower tissue mechanical prop-
erties independent of the degree of remod-
eling suppression in dogs. Furthermore, we 
and others have shown reductions in bone 
toughness with bisphosphonates in rodents, 
where intracortical remodeling does not take 
place under normal circumstances. The goal 
of the current work does not address the un-
derlying mechanism for tissue brittleness with 
bisphosphonates, but rather focuses on the 
ability of raloxifene to neutralize whatever ef-
fect has occurred. Our results suggest modi-
fication of hydration (the presumed effect of 
raloxifene) is sufficient to overcome negative 
tissue-level changes with bisphosphonates.
Although monotonic mechanical tests pro-
vide valuable information regarding properties 
of the tissue, fatigue loading tests the tissue’s 
ability to resist the initiation and propagation 
of damage leading to fracture.40 The ability 
of in vitro raloxifene exposure to alter fatigue 
properties in normal C57/B6 femora was 
clear. Raloxifene-soaked bones had nearly 2x 
longer fatigue life than normal animals, and 
even this was likely an underestimate as half 
of the raloxifene bones were stopped at 300K 
cycles (compared to one untreated bone). In-
terestingly, 7 of the 10 matched pairs showed 
higher properties in the raloxifene limb while 
three showed nearly identicalor slightly values 
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across the two limbs. Previous work assess-
ing fatigue properties of RAL bone is limited 
to experiments of cortical bones from in vivo 
treated dogs. Although monotonic tests from 
these same animals showed dramatic effects 
of in vivo treatment on mechanical properties, 
there were no differences when assessed us-
ing a cyclic relaxation test.24 The cyclic relax-
ation test differs in several ways from a tradi-
tional fatigue test, most notably in that it loads 
to progressively higher loads with the goal of 
inducing damage and then testing the abil-
ity of the tissue to resist accumulation.41 The 
link between altered hydration (the presump-
tive mechanism of effect in current soaking 
studies) and microdamage propagation re-
mains unclear but it is possible that benefits 
of hydration are more apparent in traditional 
fatigue tests.
The data presented here should be con-
sidered in the context of various limitations.
The original experiments (from which the 
bones were used) tested only males and 
only a single dose of zoledronate. Due to the 
matched design of experiment one, we did 
not have bones soaked for 7 days in control 
solution as is traditionally done in these ex-
periments. We have previously shown that 
soaking in solution does not cause the tissue 
to decalcify (which if it occurred could cause 
improved ductility).25 Although we have pre-
viously shown the main non-cellular effect of 
raloxifene is to increase hydration – measures 
of hydration in these bones was not possible. 
Finally, our fatigue data were conducted at a 
single stress level and cycle rate and cannot 
be assumed to be generalizable.
In conclusion we have shown that ex vivo 
soaking in raloxifene can act through non-
cellular mechanisms to normalize the zole-
dronate-induced brittle behavior of mouse 
bone tissue. Less robust effects were noted 
in bones from alendronate-treated dogs and 
these differences need to be further explored. 
We also document the positive effects of ral-
oxifene soaking on fatigue properties of bone.
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